Elagolix in the treatment of endometriosis: impact beyond pain symptoms

David F Archer; Ahmed M Soliman; Sanjay K. Agarwal; Hugh S Taylor

doi:10.1177/2633494120964517

Elagolix in the treatment of endometriosis: impact beyond pain symptoms

David F Archer, Ahmed M Soliman, Sanjay K. Agarwal, Hugh S Taylor

Therapeutic advances in reproductive health · 2020 · vol. 14 , pp. 2633494120964517 · doi:10.1177/2633494120964517 · PMID:33294846 · PMC7708701 · W3106937247

review OA: gold CC0 ⤵ 13 in-corpus citations

📄 Open PDF View on OpenAlex View on PubMed View at publisher

⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

Elagolix, an oral GnRH receptor antagonist, not only reduces endometriosis-associated pain but also improves quality of life, reduces fatigue, and enhances workplace and household productivity.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

While the most common symptom associated with endometriosis is pelvic pain, the systemic manifestations of the disease and the accompanying adverse psychological, emotional, social, familial, sexual, educational and workplace effects are increasingly recognized. Elagolix is an oral gonadotropin-releasing hormone receptor antagonist that is approved for the management of moderate to severe pain associated with endometriosis. However, the benefits of elagolix extend beyond reducing pain symptoms. This article reviews the non-pain systemic manifestations associated with endometriosis and summarizes the beneficial effects of elagolix on non-pain outcomes. This includes improvements in quality of life, reductions in fatigue and improvements in workplace and household productivity. These results indicate that elagolix provides non-pain benefits in women with endometriosis and improves outcomes that are clinically meaningful to patients.

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (48)

Cited by (13)

Source provenance

europepmc: last seen: 2026-06-12T06:13:51.797165+00:00
openalex: last seen: 2026-06-10T17:14:06.276822+00:00
pubmed: last seen: 2026-05-13T22:21:30.380497+00:00

License: CC0 · commercial use OK

[1] Achieving clinically meaningful response in endometriosis pain symptoms is associated with improvements in health-related quality of life and work productivity: analysis of 2 phase III clinical trials via openalex

[2] Cost–effectiveness of elagolix versus leuprolide acetate for treating moderate-to-severe endometriosis pain in the USA via openalex

[3] Current pharmacotherapy for endometriosis via openalex

[4] Economic burden of endometriosis via openalex

[5] Elagolix, an Oral GnRH Antagonist for Endometriosis-Associated Pain: A Randomized Controlled Study via openalex

[6] Elagolix, an Oral GnRH Antagonist, Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis: Effects on Bone Mineral Density via openalex

[7] Elagolix Treatment for Endometriosis-Associated Pain: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study via openalex

[8] Endometriosis via openalex

[9] Endometriosis via openalex

[10] Fatigue – a symptom in endometriosis via openalex

[11] Full-Thickness Excision versus Shaving by Laparoscopy for Intestinal Deep Infiltrating Endometriosis: Rationale and Potential Treatment Options via openalex

[12] Health-related quality of life burden of women with endometriosis: a literature review via openalex

[13] High rates of autoimmune and endocrine disorders, fibromyalgia, chronic fatigue syndrome and atopic diseases among women with endometriosis: a survey analysis via openalex

[14] Impact of elagolix on work loss due to endometriosis-associated pain: estimates based on the results of two phase III clinical trials via openalex

[15] Impact of Elagolix on Workplace and Household Productivity Among Women with Moderate to Severe Pain Associated with Endometriosis: A Pooled Analysis of Two Phase III Trials via openalex

[16] Impact of endometriosis on quality of life and mental health: pelvic pain makes the difference via openalex

[17] Impact of endometriosis on quality of life and psychological well-being via openalex

[18] Impact of endometriosis on quality of life and work productivity: a multicenter study across ten countries via openalex

[19] Long-Term Outcomes of Elagolix in Women With Endometriosis via openalex

[20] Measuring quality of life in women with endometriosis: tests of data quality, score reliability, response rate and scaling assumptions of the Endometriosis Health Profile Questionnaire via openalex

[21] Mesenteric vascular and nerve sparing surgery in laparoscopic segmental intestinal resection for deep infiltrating endometriosis via openalex

[22] Pathogenesis and pathophysiology of endometriosis via openalex

[23] Practice Bulletin No. 114: Management of Endometriosis via openalex

[24] Prevalence and Symptomatic Burden of Diagnosed Endometriosis in the United States: National Estimates from a Cross-Sectional Survey of 59,411 Women via openalex

[25] Priorities for Endometriosis Research: A Proposed Focus on Deep Dyspareunia via openalex

[26] Quality of Life Assessment Using EuroQOL EQ-5D Questionnaire in Patients with Deep Infiltrating Endometriosis: The Relation with Symptoms and Locations via openalex

[27] Quantification of the impact of endometriosis symptoms on health-related quality of life and work productivity via openalex

[28] Responsiveness Evaluation and Recommendation for Responder Thresholds for Endometriosis Health Profile-30: Analysis of Two Phase III Clinical Trials via openalex

[29] Systematic review of quality of life measures in patients with endometriosis via openalex

[30] The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres via openalex

[31] The direct and indirect costs associated with endometriosis: a systematic literature review via openalex

[32] The Effect of Endometriosis Symptoms on Absenteeism and Presenteeism in the Workplace and at Home via openalex

[33] The influence of endometriosis-related symptoms on work life and work ability: a study of Danish endometriosis patients in employment via openalex

[34] The Pathogenesis of Endometriosis: Molecular and Cell Biology Insights via openalex

[35] The significant effect of endometriosis on physical, mental and social wellbeing: results from an international cross-sectional survey via openalex

[36] The Systemic Effects of Endometriosis via openalex

[37] Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist via openalex

[38] Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist: Results from a Phase 2, Randomized Controlled Study via openalex

[39] Treatment of pelvic pain associated with endometriosis: a committee opinion via openalex

[40] Unus pro omnibus, omnes pro uno: A novel, evidence-based, unifying theory for the pathogenesis of endometriosis via openalex

[41] W2163315477 via openalex

[42] W2615713587 via openalex

[43] W2938911769 via openalex

[44] W2056209597 via openalex

[45] W2953555405 via openalex

[46] W1996855651 via openalex

[47] W3048062679 via openalex

[48] W4233562659 via openalex